Hypertension and outcomes research: From clinical trials to clinical epidemiology

American Journal of Hypertension

Volumn 9, Issue 2, 1996, Pages 178-183

  Psaty, Bruce M ^a,b   Siscovick, David S ^a,b   Weiss, Noel S ^b   Koepsell, Thomas D ^a,b   Rosendaal, Frits R ^c   Lin, Danyu ^b   Heckbert, Susan R ^b   Wagner, Edward H ^b,d   Furberg, Curt D ^e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CENTER FOR HEALTH STUDIES   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

confounding variables; drug therapy; evaluation; hypertension; inference; observational studies; randomized trials

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; ISRADIPINE; MANIDIPINE;

ANTIHYPERTENSIVE THERAPY; CONFERENCE PAPER; HUMAN; HYPERTENSION; PRIORITY JOURNAL;

EID: 0029921854     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-7061(96)00015-5     Document Type: Conference Paper

References (38)

1. Neaton JD, Grimm RH, Jr., Prineas RJ, et al for the Treatment of Mild Hypertension Research Group: Treatment of Mild Hypertension Study (TOMHS): final results. JAMA 1993;270:713-724.
2. Norris RM, White HD: Therapeutic trials in coronary thrombosis should measure left ventricular function as primary end-point of treatment. Lancet 1988;i:104-106.
3. Prentice RL: Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431-440.
4. McClellan K: Unexpected results from MIDAS in atherosclerosis [summary of results presented at the 15th Scientific Meeting of the International Society of Hypertension in Melbourne, Australia, March 1994]. Inpharma 1994;932(April 9, 1994):4.
5. Ferguson JJ, Momomura S: Meeting highlights: high-lights from the 58th annual scientific meeting of the Japanese Circulation Society. Circulation 1994;90: 2194-2196.
6. Furberg CD, Byington RP, Borhani NA, for the MIDAS Research Group: Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): design features. Am J Med 1989;86(suppl 4A):37-39.
7. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al: Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990;335:1109-1113.
8. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
9. Echt DS, Liebson PR, Mitchell LB, et al: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991;324:781-788.
10. Oliver MF, Heady JA, Morris JN, Cooper J, for the Committee of Principal Investigators: WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984;ii:600-604.
11. DiBianco R, ShabetaiR, Kostuk W, et al, for the Milrinone Multicenter Trial Group: A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-683.
12. Packer M, Craver JR, Rodeheffer RJ, et al: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.
13. Sacks HS, Berrier J, Reitman D, et al: Meta-analyses of randomized controlled trials. N Engl J Med 1987; 316:450-455.
14. Greenland S: Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:1-30.
15. Berlin JA, Longnecker MP, Greenland S: Meta-analysis of epidemiologic dose-response data. Epidemiology 1993;4:218-228.
16. Berlin JA, Laird NM, Sacks HS, Chalmers TC: A comparison of statistical methods for combining event rates from clinical trials. Stat Med 1989;8:141-151.
17. Furberg CD, Morgan TM: Lessons from overview of cardiovascular trials. Stat Med 1987;6:295-306.
18. Furberg CD, Psaty BM, Myers JV: Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331.
19. Schlesselman JJ: Case-Control Studies: Design, Conduct, Analysis. Oxford University Press, New York, 1982.
20. Breslow NE, Day NE: Statistical Methods in Cancer Research: Volume I - The Analysis of Case-Control Studies. International Agency for Research on Cancer, Lyon, France, 1980 (IARC Scientific Publications No. 32).
21. Breslow NE, Day NE: Statistical Methods in Cancer Research: Volume II - The Design and Analysis of Cohort Studies. International Agency for Research on Cancer, Lyon, France, 1987 (IARC Scientific Publications No. 82).
22. Wacholder S, McLaughlin JK, Siverman DT, Mandel JS: Selection of controls in case-control studies. I. Principles. Am J Epidemiol 1992;135:1019-1028.
23. Wacholder S, Silversman DT, McLaughlin JK, Mandel JS: Selection of controls in case-control studies. II. Types of controls. Am J Epidemiol 1992;135:1029-1041.
24. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS: Selection of controls in case-control studies. III. Design options. Am J Epidemiol 1992;135:1042-1050.
25. Petri H, Urquhart J: Channeling bias in the interpretation of drug effects. Stat Med 1991;10:577-581.
26. Stergachis A, Sheingold S, Luce BR, et al: Medical care and cost outcomes after pentoxifylline treatment for peripheral arterial disease. Arch Intern Med 1992; 152:1220-1224.
27. Kawachi I, Malcolm LA, Purdie G: Variability in antihypertensive drug therapy in general practice: results from a random national survey. NZ Med J 1989;102:307-309.
28. Payne TH, Goodson JD, Morgan MM, Barnett GO: Do resident and staff physicians differ in the types and costs of antihypertensive drugs they select? J Gen Intern Med 1991;6:439-444.
29. Weiss NS: Clinical Epidemiology: The Study of the Outcome of Illness. Oxford University Press, New York, 1986.
30. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiologic context. Lancet 1990;335:827-838.
31. Psaty BM, Koepsell TD, LoGerfo JP, et al: Beta-blockers and primary prevention of coronary heart disease in patients with high blood pressure. JAMA 1989;261:2087-2094.
32. MacMahon S, Peto R, Cutler J, et al: Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-774.
33. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
34. Dahlof B, Lindholm LH, Hansson L, et al: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338: 1281-1285.
35. Medical Research Council Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992;304:405-412.
36. Psaty BM, Furberg CD: Treatment trials: morbidity and mortality, in Izzo JL, Jr., Black HR, Taubert KA (eds): Hypertension Primer: The Essentials of High Blood Pressure. Dallas, American Heart Association, 1993, pp. 197-201.
37. Siscovick DS, Raghunathan TE, Psaty BM, et al: Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994;330:1852-1857.
38. Psaty BM, Heckbert SR, Koepsell TD, et al: The risk of myocardial infarction associated with anti-hypertensive drug therapies. JAMA 1995;274:620-625.